Skip to main content

Peer Review reports

From: Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study

Original Submission
3 Mar 2024 Submitted Original manuscript
6 Mar 2024 Author responded Author comments - Baohui Han
24 Apr 2024 Reviewed Reviewer Report - Kakeru Hisakane
2 May 2024 Reviewed Reviewer Report
16 May 2024 Author responded Author comments - Baohui Han
Resubmission - Version 2
6 Mar 2024 Submitted Manuscript version 2
19 May 2024 Reviewed Reviewer Report - Kakeru Hisakane
21 May 2024 Reviewed Reviewer Report
29 May 2024 Author responded Author comments - Baohui Han
Resubmission - Version 3
29 May 2024 Submitted Manuscript version 3
29 May 2024 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
5 Jun 2024 Editorially accepted
11 Jun 2024 Article published 10.1186/s12885-024-12479-0

You can find further information about peer review here.

Back to article page